Role Of Bradykinin

FIRAZYR is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Symptoms of an HAE attack are caused by an overproduction of bradykinin1,2

Most patients with hereditary angioedema (HAE) have an underlying deficiency in functional C1 esterase inhibitor that leads to excess bradykinin production.1,3

Pathway leading to generation of bradykinin4,5

Illustration of the pathway leading to a generation of bradykinin. Patients with HAE have an underlying deficiency in functional C1-INH that leads to an overproduction of bradykinin.

Adapted from Zuraw 2008 and Kaplan 2010.4,5

  1. An attack is initiated when the kallikrein-kinin cascade is activated6
  2. In response to activation, plasma kallikrien cleaves high-molecular-weight kininogen (HMWK), producing bradykinin6
  3. Excessive bradykinin causes an increase in blood vessel permeability, which allows fluid to pass through the blood vessel walls, causing subcutaneous or submucosal swelling2,6

FIRAZYR is the only FDA-approved bradykinin B2 receptor antagonist to treat HAE attacks7

Firazyr inhibits bradykinin from binding the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.

Adapted from Zuraw 2008 and Kaplan 2010.4,5

FIRAZYR® (icatibant injection) inhibits bradykinin from binding to the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE7